Diabetes

Alyssa Hasty, Cornelius Vanderbilt Professor of Molecular Physiology and Biophysics, specializes in immunometabolism, specifically on the role that the immune system plays in obesity and metabolic disease. Recent work from her lab explored the changes in immune cell populations in fat during obesity, weight loss, and weight cycling. Read More

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity. Read More

Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease. Read More

Vanderbilt researchers dissected the complex microenvironment of the pancreatic islet to discover the signals that drive beta cell regeneration — as a possible treatment for diabetes. Read More

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes. Read More

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy. Read More

Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study. Read More

Discovering the mechanism behind cell behavior that is a hallmark of type 2 diabetes, Vanderbilt researchers move closer to treatments for the disease, which affects 34 million Americans. Read More

The Vanderbilt Diabetes Center, the NIH-funded Diabetes Research and Training Center, and the NIH-funded Center for Diabetes Translational Research seek pilot and feasibility proposals to study the interaction of SARS-CoV-2/COVID-19 and diabetes. Read More

COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients. Read More

A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs. Read More

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity. Read More

Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication. Read More

One in nine American adults has diabetes, and one in three has pre-diabetes. Prevention and early intervention can decrease the risk of complications down the road. Read More

Research by Vanderbilt history professor Arleen Tuchman on the cultural history of diabetes offers important lessons for other public health challenges, including COVID-19. Read More

Vanderbilt cell biologists are defining the factors that help beta cells in the pancreas stay healthy, secrete insulin and prevent diabetes initiation and progression. Read More

Variation in the levels of hormones called natriuretic peptides may contribute to racial differences in susceptibility to diabetes, suggesting that this hormone system may be a target for reducing risk of the disease. Read More

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report. Read More

Shichun Bao, associate professor of medicine and the Diabetes Technology Program leader in the Division of Endocrinology at the Eskind Diabetes Clinic, shares information on the amazing technological advances in diabetes treatment and blood sugar management. Read More

The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes. Read More